Agreement formed for development of AAV vectors for ocular gene therapy

German-based company, SIRION Biotech has signed a two-year development agreement with a clinical-stage ophthalmology company, Acucela, to establish optimised adeno associated virus (AAV) vectors for clinical applications in ocular gene therapy. more

9 Jan 2018 10:55 News